Dermatology Billing: CPT Codes, Revenue Plays, and the 2021 Biopsy Code Trap

Before 2021, dermatology biopsies used a single code (11100) for the first biopsy plus an add-on (11101) for each additional. The 2021 CPT revision split biopsy coding into three technique-specific families. Tangential biopsy codes 11102 (first lesion, Work RVU 0.66, Medicare $22.05) plus 11103 add-on. Punch biopsy codes 11104 (first lesion, Work RVU 0.83, Medicare $27.77) plus 11105 add-on. Incisional biopsy codes 11106 (first lesion, Work RVU 1.01, Medicare $33.77) plus 11107 add-on. The code selection must match the technique used. Tangential biopsy removes only the epidermis and a portion of the dermis, typically using a shave or saucerization technique. Punch biopsy removes a cylindrical tissue sample including full dermis and some subcutaneous tissue. Incisional biopsy cuts into the lesion with a scalpel to take a representative sample. The revenue impact matters. Punch biopsy pays approximately $5.70 more than tangential biopsy. Incisional biopsy pays approximately $11.70 more than tangential. A dermatology practice performing 40 biopsies per week with even a 20 percent miscoding rate (using tangential when punch was actually performed) loses $237 per week or $12,320 per year from that single coding error. The fix is documentation specificity. The operative note must describe the technique clearly enough that the correct code can be assigned. Shave, saucerization, and tangential all indicate code 11102. Punch indicates 11104. Scalpel incision indicates 11106.

Actinic keratoses and other pre-malignant lesions use a specific code family that stacks based on lesion count. 17000 (destruction of first premalignant lesion, Work RVU 0.61, Medicare $20.38) covers the first lesion. 17003 (each additional lesion 2 through 14, Work RVU 0.04 per lesion, Medicare $1.34 per lesion) stacks for each additional up to 14. 17004 (destruction of 15 or more lesions, Work RVU 2.25, Medicare $75.15) covers 15 or more lesions as a single bundled code replacing 17003 stacking. The billing optimization is correct lesion counting. A patient with 8 actinic keratoses is billed 17000 plus 17003 x 7, which totals $29.76 Medicare. A patient with 20 actinic keratoses is billed 17004 single code for $75.15. A patient with 14 actinic keratoses is billed 17000 plus 17003 x 13 which totals $37.80. The critical threshold is 15 lesions. Below 15 lesions, bill 17000 plus 17003 stacked. At 15 or more lesions, bill 17004 alone. Practices that miscount or truncate at 14 when the patient actually had 16 lose the 17004 billing advantage. Documentation must specify the exact count and the anatomic location of each lesion to support the billed units.

Benign lesions (warts, seborrheic keratoses, skin tags, benign nevi) use a different code family from pre-malignant destruction. 17110 (destruction of benign lesions, up to 14, Work RVU 0.65, Medicare $21.71) covers 1 to 14 benign lesions. 17111 (destruction of benign lesions, 15 or more, Work RVU 1.09, Medicare $36.41) covers 15 or more. The code distinction between benign and pre-malignant destruction is clinical, not just nomenclature. A seborrheic keratosis removed for cosmetic reasons uses 17110. An actinic keratosis removed because it is pre-malignant uses 17000 series. Miscoding between these families triggers denials and audit risk. The diagnosis code on the claim must support the procedure code. Actinic keratosis (L57.0) supports 17000 series. Seborrheic keratosis (L82.1) supports 17110. Warts (B07.9) support 17110. The ICD-10 to CPT link determines both payment and medical necessity approval. Cosmetic removal of benign lesions is generally not covered by insurance. Documentation should clearly establish medical necessity (irritation from clothing, suspicion of malignancy, bleeding) for benign destruction to be covered.

Excision codes (11400 through 11646) include simple closure by definition. Intermediate closure (12031 through 12057) and complex closure (13100 through 13160) are separately billable on top of the excision when the wound requires deeper layered closure. The opportunity. Most excision procedures that require actual surgical closure beyond simple dermal approximation qualify for intermediate closure billing. Intermediate closure codes pay $45 to $180 depending on site and size. Missing these codes when billing excisions leaves significant revenue on the table. Intermediate closure definitions require layered closure involving one or more of the deeper layers of subcutaneous tissue and superficial fascia, in addition to the skin closure. Complex closure requires more than simple layered closure, typically involving scar revision, debridement, extensive undermining, stents, or retention sutures. A dermatology practice billing excisions should audit a month of excision claims against actual operative notes. In typical practice audits, 20 to 40 percent of excisions eligible for intermediate closure billing are coded with simple closure only. The revenue recovery for a practice performing 30 excisions per month is $1,800 to $4,000 per month in missed closure billing.

Mohs micrographic surgery is the highest-reimbursed dermatology procedure family. The codes structure each surgical stage. 17311 (first stage Mohs, Work RVU 8.11, Medicare $270.88) for the initial stage. 17312 (each additional stage, Work RVU 4.28, Medicare $142.96) for subsequent stages. 17313 (special staining first stage) for cases requiring special stains. 17314 (special staining additional stages) as the add-on. 17315 (additional specimens per stage) for cases requiring more specimens. The average Mohs case runs 1.5 to 2.2 stages depending on tumor complexity. A two-stage Mohs case bills 17311 plus 17312 totaling $413.84 Medicare. A three-stage case bills 17311 plus 17312 x 2 totaling $556.80 Medicare. The documentation requirements. Each stage must document the tissue excised, the mapping process, the histologic examination findings including positive margins requiring additional stages, and the final clear margin documentation on the last stage. Missing documentation on any stage creates audit risk. The reconstruction after Mohs (repair, flap, graft) is often billed same day as the final Mohs stage. Repair codes (12xxx, 13xxx), adjacent tissue transfer codes (14xxx), and flap codes are all separately billable from Mohs stages with appropriate modifier usage. Check payer specific rules. Some payers require separate authorization for reconstruction even when authorized for Mohs. The reconstruction may need to happen at a subsequent visit in those cases.

Dermatology E/M plus procedure billing requires careful modifier 25 application. The rule. Modifier 25 on the E/M is appropriate when the E/M service represents a significantly separately identifiable service beyond the typical pre-procedure evaluation. A new patient skin check that identifies a suspicious lesion and leads to a biopsy supports 99203 or 99204 with modifier 25 plus the biopsy code. The E/M covers the skin check of the entire body surface. The biopsy covers the specific lesion. These are separate services. A visit where the patient presents specifically for removal of a previously identified lesion does not support modifier 25 because the E/M is simply the routine pre-procedure evaluation. The OIG has flagged modifier 25 as a priority audit area. Documentation must clearly separate the E/M portion from the procedure portion. Separate history, separate exam findings for the E/M beyond the lesion site, separate medical decision making. An EHR template with clearly labeled sections reduces modifier 25 audit risk significantly. In dermatology, the modifier 25 opportunity typically applies to skin check visits where unrelated or additional lesions are identified and procedures are performed. Routine follow up visits where a pre-identified lesion is removed generally do not qualify.

Phototherapy codes cover UV light treatment for psoriasis, vitiligo, eczema, and other conditions. 96910 (photochemotherapy tar and UVB, Work RVU 0.31, Medicare $10.36) for traditional UVB. 96912 (photochemotherapy PUVA, Work RVU 0.31, Medicare $10.36) for PUVA therapy. 96913 (long duration greater than 90 minutes, Work RVU 0.62, Medicare $20.71) for extended sessions. 96920 (narrowband UVB less than 250 sq cm, Work RVU 0.42, Medicare $14.03) for targeted treatment of small areas. 96921 (narrowband UVB 250 to 500 sq cm) for medium areas. 96922 (narrowband UVB over 500 sq cm) for large body surface area treatment. Each session is separately billable. Medicare and most commercial payers cover 30 to 36 sessions per year for documented diagnoses (psoriasis L40 series, vitiligo L80, atopic dermatitis L20 series, etc.). Beyond 30 to 36 sessions, reauthorization is typically required. A psoriasis patient receiving twice-weekly phototherapy for 12 weeks (24 sessions) generates $336 to $500 in phototherapy revenue. An in-office phototherapy program with 20 active patients running 24 sessions per year each generates $6,700 to $10,000 annually in phototherapy revenue alone. Practices that own the phototherapy equipment capture both technical and professional components. Practices that do not own the equipment receive only the professional component when the facility bills the technical.

Dermatology denial patterns concentrate around coding specificity and medical necessity. CARC 97 (bundling) hits biopsy plus excision same day when both are at the same anatomic site. Fix: if biopsy and excision are at the same lesion site, bill only the excision. If at different sites, bill both with modifier 59 on the second procedure and clearly document separate anatomic locations. CARC 50 (medical necessity) fires for cosmetic-appearing procedures without documented medical necessity. Fix: document the specific reason for the procedure beyond cosmesis (bleeding, irritation, suspicion of malignancy, functional impairment). CARC 4 (modifier error) triggers for missing laterality modifiers (LT, RT) on procedures where payers require them. Fix: use LT and RT consistently on all lateralized procedures, even when not explicitly required by a specific payer. CARC 151 (frequency) hits phototherapy past coverage limits without reauthorization. Fix: track session counts per patient and submit reauthorization requests at 25 to 28 sessions for patients on active phototherapy programs. Our [denial management service](/denial-management-services) includes specialty-specific edit rules built from dermatology denial patterns.